PBC in the News

Summary News

Back

• Rising awareness and media coverage of liver diseases, particularly PBC, including expert discussions and patient stories on various platforms.
• Promising clinical trial results for new PBC treatments such as linerixibat, seladelpar (Livdelzi), and elafibranor (Iqirvo), showing improvements in symptoms like itch and fatigue.
• Regulatory progress with multiple approvals and conditional authorizations of PBC treatments across Europe, the US, and the UK (e.g., Livdelzi, Iqirvo).
• Ongoing research into the mechanisms and associated conditions of PBC, including links to lymphoma, systemic sclerosis, and gut microbiota.
• Growing investment and milestone payments in the PBC drug development sector, reflecting commercial interest and expanding treatment options.
• Studies highlighting the importance of early diagnosis, personalized treatment plans, and quality of life improvements for PBC patients.
• Concerns over safety and effectiveness of existing treatments, with regulatory bodies declining or revoking approvals (e.g., Ocaliva).
• Educational efforts through art, patient stories, and physician guidance to support awareness and understanding of rare liver diseases like PBC.

News Articles

Back

17/07/2026 Primary Sclerosing Cholangitis in an Elderly Female With Concomitant Gallstone Disease: A Diagnostic Challenge and Literature Review - Cureus

15/07/2026 Primary Biliary Cholangitis (PBC): Living With This Chronic Disease - Cleveland Clinic Health Essentials

13/07/2026 Elafibranor Achieves 85% ALP Normalization in Phase 3b ELSPIRE Trial for PBC - HCP Live

13/07/2026 Improving Disease Management in Primary Biliary Cholangitis - EMJ

13/07/2026 Advancing Primary Biliary Cholangitis Management Through Continuing Medical Education - EMJ

13/07/2026 Looking Beyond the Numbers: Addressing the Full Burden of PBC - EMJ

09/07/2026 Saroglitazar and the Evolving PBC Treatment Landscape, With Raj Vuppalanchi, MD - HCP Live

08/07/2026 Resistant primary biliary cholangitis: treatment with Elafibranor - Clínica FEHV

03/07/2026 Nearly 1 in 10 With Primary Biliary Cholangitis Have CKD - Medscape

01/07/2026 Large VA study reveals hidden liver damage in US military veterans - Liver Disease News

30/06/2026 Selective PPARα Modulator "K-808" (Pemafibrate) Granted "Breakthrough Therapy" Designation by the U.S. Food and Drug Administration (FDA) As a Treatment for Primary Biliary Cholangitis | Corporate - EQS News

30/06/2026 Selective PPARα Modulator "K-808" (Pemafibrate) Granted "Breakthrough Therapy" Designation by the U.S. Food and Drug Administration (FDA) As a Treatment for Primary Biliary Cholangitis - PR Newswire

26/06/2026 VIDEO: Treatment options vary in autoimmune biliary disease - Healio

18/06/2026 Navigating Primary Biliary Cholangitis in Singapore: Addressing the Diagnostic Gap and the Next-Generation Therapies - Yahoo Finance

17/06/2026 Scientists ID, test 2 immune proteins as possible therapeutic targets in PBC - Liver Disease News

15/06/2026 Gilead’s New Liver Approvals Reframe PBC Goals And Revenue Mix - Yahoo Finance

11/06/2026 Looking Beyond ALP Response in PBC With Saroglitazar, With Raj Vuppalanchi, MD - HCP Live

09/06/2026 Seladelpar (Livdelzi) raises the bar for primary biliary cholangitis treatment - 2 Minute Medicine

09/06/2026 PBC Linked With Higher Mortality in Patients With Diabetes or Hypertension - Renal and Urology News

08/06/2026 NICE approves seladelpar for primary biliary cholangitis - The Pharmaceutical Journal

05/06/2026 Seladelpar Given Go-Ahead by NICE for PBC Treatment - Medscape

03/06/2026 Gilead eyes PBC expansion for Livdelzi on positive one-year data - Clinical Trials Arena

03/06/2026 2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis - 2 Minute Medicine

02/06/2026 Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) - Yahoo Finance

02/06/2026 Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population - Fierce Pharma

01/06/2026 Saroglitazar Boosts Response Rates in Primary Biliary Cholangitis - MedPage Today

28/05/2026 Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to Treat Primary Biliary Cholangitis (PBC) Granted Priority Review by the US FDA - PR Newswire

28/05/2026 FDA Grants Priority Review to Saroglitazar NDA for Primary Biliary Cholangitis - HCP Live

28/05/2026 Studies at EASL Congress Could Reshape Liver Disease Prevention, Diagnosis and Care - hepmag.com

27/05/2026 Oral ABI-6250 may move into Phase 2 clinical testing for PBC and PSC - Liver Disease News

21/05/2026 Overlap Syndrome Between Autoimmune Hepatitis and Primary Sclerosing Cholangitis in a Seven-Year-Old Child: A Case Report - Cureus

21/05/2026 Driving Progress in Rare Liver Disease: Ipsen at EASL Congress 2026 - Ipsen

19/05/2026 Treatment Sequencing in Primary Biliary Cholangitis - Medscape

18/05/2026 Mesenchymal stem cells in intrahepatic and extrahepatic biliary diseases: mechanisms and therapeutic applications - Frontiers

18/05/2026 Addressing the Symptom Burden of Primary Biliary Cholangitis - Medscape

05/05/2026 Fenofibrate-UDCA Combination Therapy Safe and Effective for Primary Biliary Cholangitis - Cleveland Clinic

05/05/2026 Primary goal achieved in Mirum’s Phase IIb trial of volixibat - Clinical Trials Arena

18/04/2026 Lipidomic characterization of bile and serum reveals an altered lipid landscape in end-stage primary sclerosing cholangitis - Nature

15/04/2026 Off-label fenofibrate improves liver health in PBC patients: Study - Liver Disease News

14/04/2026 Unraveling immunological heterogeneity in recalcitrant AIH-PBC/PSC overlap syndromes: from molecular crosstalk to precision therapeutics - Frontiers

10/04/2026 How PBC Differs From Liver Cirrhosis - WebMD

10/04/2026 Early MRCP surveillance for recurrent primary sclerosing cholangitis after liver transplantation: a prospective imaging study - Nature

03/04/2026 Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial - Wiley Online Library

02/04/2026 Molecular mechanisms underlying T cell subset imbalance and precision therapeutic targets in primary biliary cholangitis - Frontiers

31/03/2026 The impact of male sex on outcomes in primary biliary cholangitis - Nature

29/03/2026 Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis - Wiley Online Library

25/03/2026 Study indicates which PBC patients may see liver function recovery - Liver Disease News

23/03/2026 Pruritus Treatment FDA Approves Lynavoy linerixibat for PBC - Gastroenterology & Endoscopy News

20/03/2026 Protect Your Well-Being With Primary Biliary Cholangitis - Everyday Health

20/03/2026 FDA approves treatment for debilitating itch in rare liver disease - Managed Healthcare Executive

19/03/2026 FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis - The American Journal of Managed Care

19/03/2026 FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis - Pharmacy Times

19/03/2026 FDA Approves Linerixibat (Lynavoy) As First Treatment for Cholestatic Pruritus in PBC - HCP Live

19/03/2026 After Alfasigma's GSK licensing deal, Lynavoy picks up FDA nod in rare liver disease - Fierce Pharma

19/03/2026 FDA OKs First Drug for Liver Disease-Related Pruritus - MedPage Today

18/03/2026 Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: A Diagnostic Challenge in a Sri Lankan Patient - Cureus

17/03/2026 Autoimmune Liver Disease and Type 2 Diabetes May Be Linked - Renal and Urology News

09/03/2026 Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision - MedCity News

09/03/2026 Alfasigma bets up to $690M on GSK’s late-stage PBC itch drug ahead of FDA decision - European Biotechnology Magazine

04/03/2026 New PBC therapy found to reduce liver scarring after 1 year in US trial - Liver Disease News

03/03/2026 COUR Pharma Announces Positive One-Year Results from the - GlobeNewswire

19/02/2026 Statin Use Linked to Lower Hepatic Decompensation Risk in Primary Biliary Cholangitis - Medscape

11/02/2026 Shifting the Clinical Conversation Around Statins in PBC, With Jonggi Choi, MD, PhD - HCP Live

11/02/2026 Primary biliary cholangitis–associated osteoporosis: contemporary review of pathogenesis and management - EurekAlert!

06/02/2026 Bezafibrate Associated With Improvement in Cholestasis for Patients With PBC - Gastroenterology Advisor

26/01/2026 Key Symptoms of PBC- Fatigue, Pruritus, and Bone Health - HCP Live

26/01/2026 An Overview of PBC Pathophysiology, Severity, and Burden - HCP Live

22/01/2026 Closing Gaps in PBC Care With Emerging and Established Second-Line Treatments - HCP Live

14/01/2026 Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review - Frontiers

12/01/2026 Bile acids as therapeutic agents - Frontiers

02/01/2026 Cholangitis in 2025: Year in Review - HCP Live

02/01/2026 Seladelpar reduced pruritus in PBC as early as ‘first month, and persisted’ - Healio

23/12/2025 Vitamin D3 attenuates hepatic inflammation in primary biliary cholangitis by inhibiting TLR4/NF-κB mediated M1 macrophage polarization | Scientific Reports - Nature

22/12/2025 Treating primary biliary cholangitis - Mayo Clinic Press

20/12/2025 S4271 Autoimmune Cholangitis: A Rare Case of... : American Journal of Gastroenterology - Lippincott Home

17/12/2025 RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis - Science | AAAS

27/11/2025 Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation - Nature

19/11/2025 Blood group A linked to a higher risk of primary biliary cholangitis - News-Medical

18/11/2025 Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists & Immunomodulators | DataM Intelligence - PR Newswire

12/11/2025 GLISTEN: Linerixibat Improves Biomarkers and Itch in Patients With PBC, With Andreas Kremer, MD, PhD, MHBA - HCP Live

11/11/2025 Long-Term Efficacy and Symptom Relief With Elafibranor in PBC, With Andreas Kremer, MD, PhD - HCP Live

10/11/2025 Seladelpar Staves Off Liver Stiffness in PBC - Medscape

10/11/2025 Seladelpar’s Impact on Liver Stiffness Measurements in PBC, With Christopher Bowlus, MD - HCP Live

09/11/2025 Elafibranor Benefits Fatigue-Related Pathways Linked to Mitochondrial Function in PBC - HCP Live

08/11/2025 Seladelpar’s Long-Term Benefit for Pruritus in PBC, With Gideon Hirschfield, FRCP, PhD - HCP Live

05/11/2025 Gilead’s Research Scholars Program Supports New Investigations into Rare Liver Disease - Gilead Sciences

05/11/2025 VIDEO: New therapies emerging in primary biliary cholangitis - Healio

27/10/2025 Exploring primary biliary cholangitis - Healio

22/10/2025 Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER) - Wiley Online Library

14/10/2025 Multi-omics tests identify novel shared genetic mechanisms of primary biliary cholestasis and sarcopenia - Nature

10/10/2025 Bezafibrate for primary biliary cholangitis: time to act on the evidence - Nature

09/10/2025 Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis - Cureus

08/10/2025 The role of mitochondria-related key genes in primary biliary cholangitis was analyzed based on transcriptome sequencing data - Frontiers

01/10/2025 PBC worst for life quality among autoimmune liver diseases: Study - Liver Disease News

15/09/2025 Common pathological mechanisms and therapeutic strategies in primary Sjogren’s syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy - Frontiers

11/09/2025 Ocaliva for PBC Withdrawn From US Market - Medscape

10/09/2025 Gilead fashions new primary biliary cholangitis campaign alongside 'Project Runway' designer - Fierce Pharma

05/09/2025 Innate immunity of bile and cholangiocytes in primary biliary cholangitis - Frontiers

01/09/2025 Beyond tired: Understanding fatigue in Primary Biliary Cholangitis - Ipsen

26/08/2025 An experimental study on the effect of symptom expectations on mental fatigue and motivation in people with primary biliary cholangitis - Nature